8-K: Cocrystal Pharma Director Dr. Anthony Japour Dies
Director Departure
Cocrystal Pharma, Inc. announced the passing of Dr. Anthony Japour, a member of its board of directors, on March 10, 2026.
Summary
- Cocrystal Pharma, Inc. reported the passing of Dr. Anthony Japour, a member of its board of directors.
- Dr. Japour passed away on March 10, 2026.
- The Form 8-K was signed and filed on March 13, 2026, by James Martin, Co-Chief Executive Officer and Chief Financial Officer.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a neutral to slightly negative event due to the loss of a board member, but it does not inherently reflect on the company's operational or financial performance.
Negatives
- The company announced the passing of Dr. Anthony Japour, a member of its board of directors.
- The company will experience a loss of expertise and experience from its board.
Risks
- Potential disruption to board operations and strategic oversight due to the unexpected vacancy.
- The company will need to identify and appoint a suitable replacement, which may take time and resources.
- Loss of specific institutional knowledge or industry connections Dr. Japour may have possessed.
Management Comments
- Cocrystal Pharma, Inc. sadly learned on March 10, 2026 that Dr. Anthony Japour, a member of the Company's board of directors, passed away.
Industry Context
StockSavvy.ai notes that the unexpected passing of a board member, particularly one with significant experience, can temporarily impact a company's governance structure and strategic continuity, though the specific impact depends on the individual's role and the depth of the remaining board.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board Member | Dr. Anthony Japour | N/A (Vacancy created) | 2026-03-10 | Passing away |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Vacancy | The passing of Dr. Anthony Japour creates a vacancy on the company's board of directors. | 2026-03-10 | This creates a temporary reduction in board size and may require the company to seek a replacement to maintain optimal governance and expertise. |
Stakeholder Impact
- Shareholders: May raise questions about board continuity and the process for appointing a successor.
- Employees: No direct impact mentioned, but could be a somber event within the company.
- Board of Directors: Loss of a colleague and potential shift in board dynamics or committee assignments.
Next Steps
- The company will likely need to initiate a process to identify and appoint a new director to fill the vacancy on the board.
Key Dates
| Date | Description |
|---|---|
| 2026-03-10 | Date Dr. Anthony Japour, a member of the Board of Directors, passed away. |
| 2026-03-13 | Date the Form 8-K was signed and filed by James Martin. |
Keywords
Cocrystal Pharma, COCP, Board of Directors, Director Departure, Corporate Governance, SEC Filing, 8-K, Anthony Japour
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.